Muriel Boreham, MD
Urogynecology and Reconstructive Pelvic Surgery · Dallas, TXNPI 1346273034
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,250 of the $12,201 with a category attached, or 67.6%. Arcutis Biotherapeutics, Inc. accounts for 67.6% of it on its own, with 24 other manufacturers making up the rest.
Across 288 payments — averaging $42.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$8K
- AbbVie$864
- Astellas Pharma US Inc$789
- Sumitomo Pharma America, Inc.$641
- Axonics, Inc.$339
- Caldera Medical, Inc$211
- plus $1K from 19 others
What the payments were for
- Consulting fees$8,25068%
- Food & beverage$3,62830%
- Education$2912%
- Gifts$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 3 | $8,250 |
| AbbVie(2 entities) | 50 | $864 |
| Astellas Pharma US Inc | 36 | $789 |
| Sumitomo Pharma America, Inc. | 97 | $641 |
| Axonics, Inc. | 18 | $339 |
| Caldera Medical, Inc | 5 | $211 |
| Convatec Inc. | 6 | $196 |
| Urovant Sciences Inc | 36 | $136 |
| Therapeuticsmd, Inc. | 8 | $135 |
| Millicent US Inc | 5 | $122 |
| Medtronic(2 entities) | 6 | $91 |
| Intuitive Surgical | 1 | $90 |
| Mission Pharmacal Company | 3 | $62 |
| Avation Medical, Inc. | 1 | $49 |
| Vertex | 2 | $41 |
| Johnson & Johnson | 1 | $33 |
| Duchesnay USA Incorporated | 2 | $26 |
| Rochester Medical Corporation | 1 | $22 |
| Zyla Life Sciences, Inc. | 1 | $21 |
| Bluewind Medical | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
| 180 Medical, Inc. | 1 | $14 |
| Boston Scientific | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,201 in reported general payments places this provider in the 85th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 626 | $591,980 |
| MyrbetriqMirabegron | 67 | $55,027 |
| Trospium Chloride | 439 | $19,569 |
| Estradiol | 263 | $19,524 |
| Mirabegron ErMirabegron | 14 | $11,325 |
| Methenamine Hippurate | 104 | $9,832 |
| ImvexxyEstradiol | 19 | $5,262 |
| Fosfomycin Tromethamine | 19 | $4,006 |
| Trospium Chloride ErTrospium Chloride | 12 | $2,877 |
| Cephalexin | 167 | $2,175 |
| Desmopressin Acetate | 47 | $1,699 |
| Clobetasol Propionate | 57 | $1,692 |
| Heparin SodiumHeparin Sodium,porcine | 49 | $1,602 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 139 | $1,582 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 167 | $1,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $641 | $591,980626 claims |
| Astellas Pharma US IncMyrbetriq | $789 | $55,02767 claims |
| Therapeuticsmd, Inc.Imvexxy | $135 | $5,26219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Dallas
- Benjamin SmithDallas$9K
- Paul SlocumDallas$9K
- Michael CarleyDallas$7K
- Kari KubikDallas$3K
- Shani AroraDallas$2K
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.